In an effort to provide a diversity of viewpoints on pressing questions related to biopharma financing and funding in 2023, Life Science Leader reached far and wide in soliciting executive responses to questions featured in our December Industry Outlook 2023 special issue. We greatly appreciate the volume and quality of responses received from leaders across the industry, many of which appeared in the print magazine: those finance and funding questions and responses can be found here. The following collection of responses did not appear in the December magazine, due to space constraints, and are presented here as part one of a three-part online supplement aimed at providing additional insights on financing, funding and manufacturing products in 2023.
There are several pathways for companies who are in the position of having to postpone or cancel an initial public offering, with each having its own benefits and challenges. One option is looking at a hybrid model of supplementing a portion of the desired equity financing with the concurrent issuance of a “responsible” level of debt. For the debt financing portion, there is also the possibility of some of those lenders converting that debt into equity over time.
